ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc (BCRX)

8.09
0.47
(6.17%)
Closed February 04 3:00PM
8.09
0.00
( 0.00% )
Pre Market: 3:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
8.09
Bid
8.10
Ask
8.15
Volume
-
0.00 Day's Range 0.00
4.03 52 Week Range 8.88
Market Cap
Previous Close
8.09
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
2,062,267
Shares Outstanding
207,132,571
Dividend Yield
-
PE Ratio
-7.40
Earnings Per Share (EPS)
-1.09
Revenue
331.41M
Net Profit
-226.54M

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, ... BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
BioCryst Pharmaceuticals Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker BCRX. The last closing price for BioCryst Pharmaceuticals was US$8.09. Over the last year, BioCryst Pharmaceuticals shares have traded in a share price range of US$ 4.03 to US$ 8.88.

BioCryst Pharmaceuticals currently has 207,132,571 shares outstanding. The market capitalization of BioCryst Pharmaceuticals is US$1.68 billion. BioCryst Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.40.

BCRX Latest News

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

—ORLADEYO net revenue expected to be between $515-$535 million in 2025— —Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025— —Company achieved operating profit in...

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan...

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.172.146464646467.928.147.5420964577.89931118CS
4-0.02-0.2466091245388.118.496.9625505897.68206767CS
120.172.146464646467.928.496.9220622677.58881794CS
261.4121.10778443116.688.886.4920667337.6939863CS
523.0560.51587301595.048.884.0326990186.50701921CS
156-7.09-46.706192358415.1819.994.0330564438.85880531CS
2605.02163.5179153093.0719.991.5841278428.21950817CS

BCRX - Frequently Asked Questions (FAQ)

What is the current BioCryst Pharmaceuticals share price?
The current share price of BioCryst Pharmaceuticals is US$ 8.09
How many BioCryst Pharmaceuticals shares are in issue?
BioCryst Pharmaceuticals has 207,132,571 shares in issue
What is the market cap of BioCryst Pharmaceuticals?
The market capitalisation of BioCryst Pharmaceuticals is USD 1.68B
What is the 1 year trading range for BioCryst Pharmaceuticals share price?
BioCryst Pharmaceuticals has traded in the range of US$ 4.03 to US$ 8.88 during the past year
What is the PE ratio of BioCryst Pharmaceuticals?
The price to earnings ratio of BioCryst Pharmaceuticals is -7.4
What is the cash to sales ratio of BioCryst Pharmaceuticals?
The cash to sales ratio of BioCryst Pharmaceuticals is 5.06
What is the reporting currency for BioCryst Pharmaceuticals?
BioCryst Pharmaceuticals reports financial results in USD
What is the latest annual turnover for BioCryst Pharmaceuticals?
The latest annual turnover of BioCryst Pharmaceuticals is USD 331.41M
What is the latest annual profit for BioCryst Pharmaceuticals?
The latest annual profit of BioCryst Pharmaceuticals is USD -226.54M
What is the registered address of BioCryst Pharmaceuticals?
The registered address for BioCryst Pharmaceuticals is 2711 CENTERVILLE ROAD, NEW CASTLE, WILMINGTON, DELAWARE, 19808
What is the BioCryst Pharmaceuticals website address?
The website address for BioCryst Pharmaceuticals is www.biocryst.com
Which industry sector does BioCryst Pharmaceuticals operate in?
BioCryst Pharmaceuticals operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
OPOFOld Point Financial Corporation
US$ 39.51
(58.99%)
4
TWINTwin Disc Inc
US$ 17.88
(58.93%)
27
IBACIB Acquisition Corporation
US$ 16.24
(58.90%)
2
ADSEADD TEC Energy PLC
US$ 23.39
(56.66%)
12
AFRIForafric Global PLC
US$ 14.99
(56.15%)
19
SBFGSB Finanical Group Inc
US$ 12.22
(-46.85%)
10
THRYThryv Holdings Inc
US$ 10.01
(-46.01%)
4
IROQIF Bancorp Inc
US$ 15.00
(-38.17%)
200
AURAAura Biosciences Inc
US$ 5.01
(-37.38%)
1
WMPNWilliam Penn Bancorporation
US$ 8.00
(-35.22%)
201
CYNCYNGN Inc
US$ 0.0793
(11.69%)
12.52M
SXTP60 Degrees Pharmaceuticals Inc
US$ 0.8758
(46.70%)
9.63M
UPCUniverse Pharmaceuticals Inc
US$ 0.325
(20.41%)
5.51M
SFHGSamfine Creation Holdings Group Ltd
US$ 1.50
(50.00%)
5.01M
RIMEAlgorhythm Holdings Inc
US$ 0.026
(6.56%)
4.26M

BCRX Discussion

View Posts
rosemountbomber rosemountbomber 3 weeks ago
What is going on here, stock price whipsawed from one day to the next. Doesn't seem like any rhyme or reason.
👍️0
Monksdream Monksdream 1 month ago
BCRX, under $8
👍️0
Monksdream Monksdream 3 months ago
BCRX under $10

👍️0
Monksdream Monksdream 6 months ago
BCRX under $8
👍️0
Monksdream Monksdream 9 months ago
BCRX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
BCRX new 52 lo
👍️0
Monksdream Monksdream 10 months ago
BCRX new 52 week lo
👍️0
Monksdream Monksdream 10 months ago
BCRX under $10
👍️0
Monksdream Monksdream 11 months ago
BCRX 10Q 2/26
👍️0
Calcumad Calcumad 1 year ago
It is turning around. Just let the big guys manipulate it enough so they can collect from the shorting and then buy cheaper
👍️0
james kent james kent 1 year ago
when will it turn around?
👍️0
james kent james kent 1 year ago
when will it turn around?
👍️0
ttubular ttubular 2 years ago
Huge buys in AH
👍️0
VivaLasVegas VivaLasVegas 2 years ago
Why is this symbol now taking a digger with all the rest?
What did Stoney do or not do?
👍️0
ttubular ttubular 3 years ago
6:58a ET 8/4/2022 - Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Mentioned: BCRX
EQNX::TICKER_START (NASDAQ:BCRX), EQNX::TICKER_END BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Clinical evidence and recent laboratory studies have informed the company's hypothesis that crystals form in the kidneys of some patients. The company believes that lowering the dose to 400 mg and ensuring adequate hydration will dilute the concentration of drug in the urine below the threshold where crystals can form.
👍️0
rosemountbomber rosemountbomber 3 years ago
Don’t have the link but apparently Denner sold a bunch of BCRX 05/16/2022.
👍️0
conix conix 3 years ago
BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by stock analysts at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Monday, The Fly reports. They presently have a $13.00 price target on the biotechnology company’s stock, down from their previous price target of $22.00. Barclays‘s price objective suggests a potential upside of 14.14% from the stock’s current price.

BCRX has been the subject of a number of other research reports. Piper Sandler restated an “in-line” rating and issued a $24.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 23rd. Evercore ISI lowered their target price on shares of BioCryst Pharmaceuticals from $25.00 to $15.00 in a research note on Friday, April 8th. StockNews.com assumed coverage on shares of BioCryst Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Finally, Oppenheimer lowered their target price on shares of BioCryst Pharmaceuticals from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Monday, April 11th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $19.09.
👍️0
Cosa Cosa 3 years ago
I guess it was perfect timing in a way...
👍️0
Cosa Cosa 3 years ago
I reduced my position here to buy more AUPH (facepalm)
👍️0
starkd748 starkd748 3 years ago
13.90s pullback yesss
👍️0
starkd748 starkd748 3 years ago
Overbought pullback in progress TA saves money
👍️0
Limey42 Limey42 3 years ago
You were saying? LMFAO!!!!!!!!
👍️0
game7alcs game7alcs 3 years ago
BCRX just on CNBC for large call volume action
👍️0
starkd748 starkd748 3 years ago
Burnt to a crisp rsi enjoy
👍️0
starkd748 starkd748 3 years ago
Lmfao the rsi is 100 pullback in progress
👍️0
ttubular ttubular 3 years ago
Understatement
👍️0
Limey42 Limey42 3 years ago
This company is a juggernaut!
👍️0
plexrec plexrec 3 years ago
Worldwide addressable market ??? Any estimate what kind of sales company is targeting ??? Totals ???? Rare diseases etc ????? TIA
👍️0
ezyE ezyE 3 years ago
Great buying opportunity.
Shouldn't be this low.
👍️0
easyrider1 easyrider1 3 years ago
What a complete manipulation to knock this down to get cheap stock. IMHO, the best low priced play in the market. The earnings report wil get this th $18 Total disregard for upgrades etc. this is a buying opportunity.
👍️0
easyrider1 easyrider1 3 years ago
Total joke to knock this down under $15 with all the positive news in the short term. Cashing in my soda bottles to buy more
👍️0
starkd748 starkd748 3 years ago
Might buy some options here
👍️0
easyrider1 easyrider1 3 years ago
Strongest day since the ill fated secondary announcement and we held most of the gains. Now we need volume.
👍️0
MZlu MZlu 3 years ago
I remember in recent weeks, we have seen some PR operations which I don't know if they were initiated by BioCryst:
- They won a prize for R&D
- They won a prize for marketing
- Barron's did a favorable mention of the Company
Looks like the big boys are shifting the narrative.
👍️0
easyrider1 easyrider1 3 years ago
First sign of life….someone realizes that this a buy
👍️0
Deano361 Deano361 3 years ago
Yeah been 18 months now and holding for me . I thin pnh results soon will help us
👍️0
easyrider1 easyrider1 3 years ago
I can’t believe that we are trending downward and broke $14. I keep buying a tad on each dip, but the dips are getting lower. I don’t understand what I’m missing with the breakout sales and potential for nearing profitability and real potential for a buyout.

This is still one of my favorite holdings but so disappointing since the Mgmt’s botched secondary attempt and lack of credible explanation.
👍️0
Deano361 Deano361 3 years ago
Yes two positive things going on . The new drug getting approvals and revenue and the pnh upcoming fast track trials
👍️0
Cosa Cosa 3 years ago
The sharp increase in revenue is what got my attention!
👍️0
Cosa Cosa 3 years ago
"Facepalm" I jinxed you guys.
👍️0
bhulkupk bhulkupk 3 years ago
Hi Cosa, welcome…
👍️0
Deano361 Deano361 3 years ago
Hi, been in since March/april 2020 from $3s. The key to this stock are upcoming 4Q results from PNH. PNH positive data makes this a $100 stock in 18 months IMO. Keep an eye on warrants and data.
👍️0
Cosa Cosa 3 years ago
Hello All, new here. Grabbed a little just to have in my portfolio to keep an eye on this. Looks like its been consolidating for almost 5 months! Still doing DD.
👍️0
easyrider1 easyrider1 3 years ago
Can’t believe with all the recent news especially appointment of Galson to the board and connections with Amgen that we’re not at $20 by now. The dip to the low $14’s was a gift.

More publications are suggesting that Bcrx is one off the best stock pics of the year. This is my favorite stock as I continue to accumulate…..doesn’t seem like there is anything but strong upside
👍️0
Deano361 Deano361 3 years ago
Well, it’s one of my few long 3 year stocks IMO . Started at $3 last year
👍️0
bhulkupk bhulkupk 3 years ago
Oh okay, so I can buy some for long term? Thanks in advance.
👍️0
Deano361 Deano361 3 years ago
It’s a quote from executive and it’s all about pnh for the future . Pnh is going to be Golden !!
👍️0
bhulkupk bhulkupk 3 years ago
How?
👍️0
Limey42 Limey42 3 years ago
Embarrassment of riches!
👍️0
MZlu MZlu 3 years ago
I think it is a public show of the poison pill clause. There may have been a potential buyer who wanted to play hard ball but got cock-blocked by Jon "Biochad" Stonehouse.
👍️0

Your Recent History

Delayed Upgrade Clock